ClinicalTrials.gg
Status unknownNCT01151826Updated Mar 2, 2011

Quantifying Physical and Biochemical Factors That Contribute to Primary Graft Dysfunction After Lung Transplantation

An observational study in Primary Graft Dysfunction, sponsored by University Hospital, Strasbourg, France. Status unknown at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-02.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified Mar 2011), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Study summary

Primary graft dysfunction (PGD or lung reperfusion edema) complicates 10 to 20% of lung transplantations and leads to severe early and late postoperative complications. Its pathophysiology remains unclear but may involve graft ischemia-reperfusion, increased vascular permeability, pneumocyte dysfunction and finally alveolar flooding that impair gas exchange and blood oxygenation.Its substrate, namely extravascular lung water (EVLW), can now be clinically measured with minimally invasive Intensive Care Unit monitors (PiCCO2®, Pulsion Medical Systems) that also provides a physical estimate of pulmonary vascular permeability (PVPI). Similarly, biochemical correlates of vascular permeability (ICAM-1) and pneumocyte dysfunction (RAGE) can now be measured in plasma samples. Our study aims at quantifying physical and biochemical markers of PGD and assess their diagnosis and prognosis values.

02

Conditions studied

  • Primary Graft Dysfunction

Keywords

  • Lung transplantation
  • Primary Graft Dysfunction
  • Extravascular Lung Water
  • Receptor for Advanced Glycation Endproducts (RAGE)
  • Intercellular Adhesion Molecule-1 (ICAM-1)
03

In context

Primary Graft Dysfunction

26 studies on the registry are indexed under Primary Graft Dysfunction; 4 are open to participants now.

This study's planned enrollment of 45 is below the median of 60 across 13 observational studies indexed under Primary Graft Dysfunction.

Browse Primary Graft Dysfunction studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Lung transplant recipients cared for in Surgical Intensive Care Unit in Strasbourg University Hospital, France

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lung transplant recipient
  • Age > 18 years
  • Signed
  • Social security affiliation

Exclusion criteria

Exclusion Criteria:

  • Age\<18
  • Pregnancy or lactation
  • to femoral arterial catheterization
  • Patient refusal
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
06

What researchers measure

Primary outcomes

  1. Diagnosis and prognosis values of extravascular lung water (EVLW) and pulmonary vascular permeability index (PVPI).

    Time frame: H0 (At started lung transplantation), H6, H12, H24, H48, H72 after lung transplantation

Secondary outcomes

  1. Diagnosis and prognosis values of receptor for advanced glycation endproducts (RAGE) and intercellular adhesion

    Time frame: H0 (At started lung transplantation), H6, H12, H24, H48, H72 after lung transplantation

07

Study locations

4 of 4 sites recruiting
  • Service de Chirurgie thoracique - Nouvel Hôpital Civil - 1, Place de l'hôpital
    Strasbourg Cedex, 67091, France
    Recruiting
    • Gilbert MASSARD, MD · ContactGilbert.Massard@chru-strasbourg.fr · 33 3 69 55 07 98
    • Gilbert MASSARD, MD · Principal investigator
    • Pierre-Emmanuel FALCOZ, MD · Sub investigator
    • Nicola SANTELMO, MD · Sub investigator
  • Service de Physiologie et d'Explorations fonctionnelles - Nouvel Hôpital Civil - 1, Place de l'hôpital
    Strasbourg Cedex, 67091, France
    Recruiting
    • Bernard GENY, MD · ContactBernard.Geny@chru-strasbourg.fr · 33 3 69 55 08 79
    • Bernard GENY, MD · Principal investigator
    • Anne CHARLOUX, MD · Sub investigator
  • Service de Pneumologie - Nouvel Hôpital Civil -1, Place de l'hôpital
    Strasbourg Cedex, 67091, France
    Recruiting
    • Romain KESSLER, MD · ContactRomain.Kessler@chru-strasbourg.fr · 33 3 69 55 06 45
    • Romain Kessler, MD · Principal investigator
    • Armelle SCHULLER, MD · Sub investigator
    • Matthieu CANUET, MD · Sub investigator
    • Sandrine HIRSCHI, MD · Sub investigator
  • Service d'Anesthésie-Réanimations chirurgicales - Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67091, France
    Recruiting
    • Julien Pottecher, MD · Contactjulien.pottecher@chru-strasbourg.fr · 33 3 69 55 04 44
    • Julien Pottecher, MD · Principal investigator
    • Jean-Pierre DUPEYRON, MD · Sub investigator
    • Olivier HELMS, MD · Sub investigator
    • Jean-Gustave HENTZ, MD · Sub investigator
    • François LEVY, MD · Sub investigator
    • Jean-Claude RIGOLOT, MD · Sub investigator
    • Anne-Claude ROCHE, MD · Sub investigator
    • Régine CUNY, MD · Sub investigator
    • Marie-Odile LEBOUBE, MD · Sub investigator
08

References and documents

Publications

  • Pottecher J, Roche AC, Degot T, Helms O, Hentz JG, Schmitt JP, Falcoz PE, Santelmo N, Levy F, Collange O, Uring-Lambert B, Bahram S, Schaeffer M, Meyer N, Geny B, Lassalle P, Diemunsch P, Massard G, Kessler R, Steib A; Groupe de Transplantation Pulmonaire des Hopitaux Universitaires de Strasbourg. Increased Extravascular Lung Water and Plasma Biomarkers of Acute Lung Injury Precede Oxygenation Impairment in Primary Graft Dysfunction After Lung Transplantation. Transplantation. 2017 Jan;101(1):112-121. doi: 10.1097/TP.0000000000001434. PubMed 27495752 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2010
First posted
Jun 28, 2010
Start
Jul 2010
Primary completionEst.
Aug 2012
CompletionEst.
Aug 2012
Last update
Mar 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01151826
First posted
Jun 28, 2010
Start date
Jul 2010
Primary completion
Aug 2012 (estimated)
Completion
Aug 2012 (estimated)
Last update
Mar 2, 2011

Study contacts

Julien Pottecher, MD
Contact
julien.pottecher@chru-strasbourg.fr
33 3 69 55 04 44
Julien Pottecher, MD
study director · Service d'Anesthésie-Réanimations chirurgicales - Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg Strasbourg, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion